X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2010) 2010
Publication (193) 193
Newspaper Article (173) 173
Book Review (56) 56
Newsletter (40) 40
Book / eBook (21) 21
Book Chapter (18) 18
Trade Publication Article (13) 13
Transcript (8) 8
Magazine Article (7) 7
Data Set (2) 2
Dissertation (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1241) 1241
index medicus (1190) 1190
oncology (955) 955
patients (875) 875
cancer (715) 715
care and treatment (611) 611
hematology (559) 559
female (521) 521
chronic myeloid leukemia (519) 519
leukemia (519) 519
male (508) 508
research (485) 485
chemotherapy (459) 459
middle aged (435) 435
patient outcomes (430) 430
imatinib (414) 414
adult (410) 410
antineoplastic agents - therapeutic use (386) 386
drug therapy (385) 385
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (363) 363
chronic myelogenous leukemia (355) 355
aged (343) 343
imatinib mesylate (339) 339
health aspects (331) 331
cancer therapies (328) 328
treatment outcome (306) 306
clinical trials (304) 304
tumors (303) 303
protein kinase inhibitors - therapeutic use (281) 281
mutation (278) 278
patients receiving imatinib (276) 276
risk factors (256) 256
kinases (255) 255
chronic myeloid-leukemia (253) 253
metastasis (252) 252
therapy (247) 247
medicine (240) 240
hemic and lymphatic diseases (238) 238
follow-up (234) 234
pyrimidines - therapeutic use (218) 218
pharmacology & pharmacy (211) 211
tyrosine kinase inhibitors (209) 209
dasatinib (208) 208
studies (208) 208
tyrosine (204) 204
medical research (200) 200
antineoplastic agents (198) 198
tyrosine kinase inhibitor (197) 197
antineoplastic agents - adverse effects (195) 195
drug dosages (192) 192
prognosis (190) 190
diagnosis (189) 189
analysis (187) 187
medical prognosis (185) 185
antimitotic agents (183) 183
piperazines - therapeutic use (178) 178
benzamides (177) 177
young adult (171) 171
research article (166) 166
review (166) 166
adolescent (165) 165
nilotinib (163) 163
stem cells (162) 162
survival (159) 159
complications and side effects (153) 153
aged, 80 and over (152) 152
animals (152) 152
genetic aspects (150) 150
leukemia, myelogenous, chronic, bcr-abl positive - genetics (148) 148
transplantation (139) 139
antineoplastic agents - administration & dosage (138) 138
bcr-abl (138) 138
dosage and administration (138) 138
development and progression (137) 137
chronic-phase (136) 136
stem-cell transplantation (136) 136
usage (128) 128
cml (126) 126
myeloid leukemia (125) 125
protein-tyrosine kinase (125) 125
proteins (123) 123
bone marrow (120) 120
protein kinase inhibitors - adverse effects (120) 120
quality of life (120) 120
fusion proteins, bcr-abl - genetics (119) 119
neoplasms - drug therapy (119) 119
cancer patients (118) 118
pharmaceutical industry (115) 115
retrospective studies (112) 112
methods (111) 111
neoplasms. tumors. oncology. including cancer and carcinogens (111) 111
pyrimidines - adverse effects (111) 111
immunology (109) 109
science (107) 107
toxicity (107) 107
clinical trials as topic (104) 104
drugs (102) 102
medicine & public health (102) 102
gene expression (101) 101
protein-tyrosine kinases - antagonists & inhibitors (101) 101
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (11) 11
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Gerstein Science - Circulation Desk (2) 2
Credit Valley Hospital - Special Collections (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Markham Stouffville Hospital - Storage (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Toronto East General Hospital - Online (1) 1
Trillium Health Centre - Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2278) 2278
German (5) 5
French (4) 4
Russian (2) 2
Chinese (1) 1
Portuguese (1) 1
Slovenian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Haematologica, ISSN 0390-6078, 02/2013, Volume 98, Issue 2, pp. 193 - 200
Imatinib has so far been the first-choice treatment in chronic myeloid leukemia with excellent results. However, only a proportion of patients achieve major... 
CHRONIC MYELOGENOUS LEUKEMIA | CHRONIC-PHASE | LOW OCT-1 ACTIVITY | STANDARD-DOSE IMATINIB | TYROSINE KINASE INHIBITOR | MDR1 GENE | FOLLOW-UP | DRUG-RESISTANCE | HEMATOLOGY | MULTIDRUG-RESISTANCE GENE | CML PATIENTS | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Benzamides - metabolism | Cytochrome P-450 Enzyme System - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Piperazines - metabolism | Antineoplastic Agents - therapeutic use | Pyrimidines - metabolism | Antineoplastic Agents - metabolism | Young Adult | Benzamides - therapeutic use | Cytochrome P-450 CYP3A - genetics | Cation Transport Proteins - metabolism | Adult | Cation Transport Proteins - genetics | Female | Organic Cation Transport Proteins - metabolism | Genotype | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Cytochrome P-450 CYP3A - metabolism | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Alleles | Cytochrome P-450 Enzyme System - genetics | Aged | Polymorphism, Single Nucleotide | Organic Cation Transport Proteins - genetics | Protein Kinase Inhibitors - metabolism
Journal Article
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 10, pp. 917 - 927
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2010, Volume 362, Issue 24, pp. 2251 - 2259
The treatment of chronic myeloid leukemia (CML) achieved a great leap forward with the development of imatinib, a BCR-ABL kinase inhibitor. Alterations in the... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | PHASE CML-CP | MOLECULAR RESPONSES | UP SUSTAINED SURVIVAL | 800 MG | HARMONIZING CURRENT METHODOLOGY | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | PATIENTS PTS | BCR-ABL TRANSCRIPTS | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Blast Crisis - prevention & control | Protein Kinase Inhibitors - adverse effects | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Kaplan-Meier Estimate | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Benzamides | Nilotinib | Antiviral agents | Safety and security measures | Chronic myeloid leukemia | Drug therapy | Comparative analysis | Clinical trials | Drug dosages | Medical treatment | bcr-abl | pathology | Leukemia | Chronic-Phase | Myeloid | Klinisk medicin | 80 and over | Pyrimidines | administration & dosage | Fusion Proteins | Blast Crisis | drug therapy | Piperazines | Antineoplastic Agents | prevention & control | antagonists & inhibitors | Clinical Medicine | Protein Kinase Inhibitors | adverse effects | therapeutic use
Journal Article
Archives of Gynecology and Obstetrics, ISSN 0932-0067, 4/2017, Volume 295, Issue 4, pp. 1059 - 1059
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00404-017-4321-0 
Human Genetics | Medicine & Public Health | Gynecology | Endocrinology | Obstetrics/Perinatology | Antimitotic agents | Antineoplastic agents | Pregnant women | Patient outcomes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2010, Volume 362, Issue 24, pp. 2260 - 2270
Journal Article
Molecular Carcinogenesis, ISSN 0899-1987, 12/2014, Volume 53, Issue 12, pp. 951 - 959
Journal Article
Archives of Gynecology and Obstetrics, ISSN 0932-0067, 2/2017, Volume 295, Issue 2, pp. 269 - 271
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00404-016-4262-z 
Human Genetics | Medicine & Public Health | Gynecology | Endocrinology | Obstetrics/Perinatology | OBSTETRICS & GYNECOLOGY | Antimitotic agents | Antineoplastic agents | Pregnant women | Patient outcomes
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 04/2011, Volume 103, Issue 7, pp. 553 - 561
Background Imatinib slows development of chronic myeloid leukemia (CML). However, available information on morbidity and mortality is largely based on... 
MESYLATE | RESPONSES | INTERFERON | THERAPY | ONCOLOGY | SAFETY | RESISTANCE | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | Piperazines - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Polymerase Chain Reaction | Adult | Female | Odds Ratio | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Benzamides | Development and progression | Care and treatment | Chronic myeloid leukemia | Research | Drug therapy | Patient outcomes | Edema | Imatinib | Statistical analysis | Mortality | Sex | Clinical trials | Diarrhea | Muscles | Survival | Morbidity | Hemopoiesis | Philadelphia chromosome | Tendons | Polymerase chain reaction | Side effects | Asthenia | Remission | Ligaments | Index Medicus
Journal Article